Page 2 - பல்கலைக்கழகம் ஆஃப் உட்டா மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more  Credit: Huntsman Cancer Institute PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021. Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose in

United statesDana farber cancer instituteMegan othusJustinev cohenJohnm kirkwoodTeresam petrellaAntoni ribasBartosz chmielowskiKennethf grossmannKari kendraPauline funchainKrishnas gunturuThach giao truongAhmad tarhiniKarld lewisVernonk sondak